![Can Ophthalmic Biomarkers Offer Insights into Brain Pathologies?](https://www.g2intelligence.com/wp-content/uploads/2023/07/Aug23.DTET_.EyeAD-iStock-485261444_1100x800-1080x675.jpg)
Can Ophthalmic Biomarkers Offer Insights into Brain Pathologies?
Protein levels in the vitreous humor may have the potential to support the diagnosis and staging of neurodegenerative diseases.
Protein levels in the vitreous humor may have the potential to support the diagnosis and staging of neurodegenerative diseases.
A new assay uses AI-optimized enzymes to simplify and increase the accuracy of rapid pathogen detection.
Accessible screening tests and inclusive management strategies may limit the global cervical cancer incidence rate.
New program aims to provide greater transparency on the recommended performance characteristics of such tests.
Recently released Centers for Medicare and Medicaid Services guidance shares when CLIA regulations apply to international labs.
Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.
Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.
False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.
Here’s what to know about the new codes that CMS recently added to the national HCPCS table as well as which ones were removed.
Key approvals announced in June represented important steps forward for the lab testing industry.